A Phase 2 interventional study of OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL and Placebo in Inflammation Corneal and Pain, Postoperative, sponsored by Oculis. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by Oculis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Keratitis with a site in United States — 4 open to participants now, 4 under way, 1 of them phase 3. Keratitis · United States.
Among the 34 studies in Keratitis with a site in United States, this one is the 8th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2019, is one of 9 in phase 2, and was the 19th registered.
108 studies on the registry are indexed under Keratitis; 19 are open to participants now.
Browse Keratitis studies →4 of the 34 studies in Keratitis with a site in United States are open now. Recruiting first, the newest first:
TearSolutions, Inc. · Sites in United States
Ages 18+
Krystal Biotech, Inc. · Sites in United States
Ages 18+
BRIM Biotechnology Inc. · Sites in United States
Ages 18+
Stanford University · Sites in United States, Brazil, India
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Keratitis studies recruiting now, 6 set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 5 · Phase 4 3
First in 1997; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 153 is above the median of 40 across 70 interventional studies indexed under Keratitis.
Median enrollment 60 across the 25 interventional studies, 60 across the 9 observational. Of the 26 that completed or were terminated, 13 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 34 have an industry lead sponsor. The 10 most frequent:
Oculis is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
Oculis has 1 study filed under Keratitis — fewer than ten, so there is no comparison to draw.
2 of the studies in Keratitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06999733Krystal Biotech, Inc.A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis | 2026-12 |
| NCT07568730TearSolutions, Inc.A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 34 studies in Keratitis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The DX-216 trial is a randomized, double-masked, placebo (vehicle)-controlled study evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle in the treatment of inflammation and pain following cataract surgery. The primary objective is to evaluate the efficacy and safety of OCS-01 compared to placebo and the secondary objective is to evaluate the optimal dosing frequency (once a day [QD] or twice a day [BID]).
This is a multi-center, randomized, double-masked, placebo (vehicle)-controlled study, designed to evaluate the efficacy and safety of OCS-01 ophthalmic suspension (QD versus BID) compared to placebo in treating inflammation and pain following cataract surgery. Subjects will be randomized 1:1:1 to receive OCS-01 QD, OCS-01 BID, or placebo BID. Subjects will dose 1 drop in the study eye BID for 14 days, beginning 1 day post-surgery in the operated eye. The study will last up to 24 days, including a follow-up visit at Visit 7 (Day 22 ± 2).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
eye drops
Drug: OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL · Drug: Placebo
eye drops
Drug: OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL
eye drops
Drug: Placebo
OCS-01 eye drops
Also known as: DexNP
Vehicle eye drops
Also known as: Vehicle
Number of Subjects With Absence of Anterior Chamber Cells (i.e. Score of '0')
Absence of anterior chamber cells as measured by slit beam with fluorescein. The anterior chamber cell count was recorded as the actual number of cells observed if ≤10 cells were seen, otherwise a range was reported. The observed anterior chamber cell count at Visit 6 was used and categorized for analysis as follows: * Absence of anterior chamber cells: anterior chamber cell count of 0 / Grade 0 * Presence of anterior chamber cells: anterior chamber cell count of 1 or more / Grade 1, 2, 3, or 4
Time frame: at Day 15 (visit 6)
Number of Subjects With Absence of Ocular Pain (i.e. Score of '0')
Absence of pain as assessed by Ocular Pain Grading Scale (Min 0, Max 10) in which 0 is no pain and 10 is the worst possible. Ocular pain was assessed by the patient at screening and at each follow-up visit, utilizing a numerical pain rating scale. Scores ranged from 0 to 10, where 0 = No Pain and 10 = Severe Pain, such that larger scores corresponded to higher levels of pain.
Time frame: at Day 4 (visit 4)
| Milestone | OCS-01 1.5% mg/mL QD | OCS-01 1.5% mg/mL BID | Placebo (Vehicle) BID |
|---|---|---|---|
| Started | 51 | 51 | 51 |
| Completed | 50 | 50 | 48 |
| Not completed | 1 | 1 | 3 |
Absence of anterior chamber cells as measured by slit beam with fluorescein. The anterior chamber cell count was recorded as the actual number of cells observed if ≤10 cells were seen, otherwise a range was reported. The observed anterior chamber cell count at Visit 6 was used and categorized for analysis as follows: * Absence of anterior chamber cells: anterior chamber cell count of 0 / Grade 0 * Presence of anterior chamber cells: anterior chamber cell count of 1 or more / Grade 1, 2, 3, or 4
| participants | OCS-01 1.5% mg/mL QD | OCS-01 1.5% mg/mL BID | Placebo (Vehicle) BID |
|---|---|---|---|
| Number of Subjects With Absence of Anterior Chamber Cells (i.e. Score of '0') | 26 | 34 | 10 |
Absence of pain as assessed by Ocular Pain Grading Scale (Min 0, Max 10) in which 0 is no pain and 10 is the worst possible. Ocular pain was assessed by the patient at screening and at each follow-up visit, utilizing a numerical pain rating scale. Scores ranged from 0 to 10, where 0 = No Pain and 10 = Severe Pain, such that larger scores corresponded to higher levels of pain.
| participants | OCS-01 1.5% mg/mL QD | OCS-01 1.5% mg/mL BID | Placebo (Vehicle) BID |
|---|---|---|---|
| Number of Subjects With Absence of Ocular Pain (i.e. Score of '0') | 37 | 32 | 23 |
Collected over The AEs were queried at visit 2 (Day 1, 18 - 30h post surgery), visit 4 (Day 4) , visit 5 (Day 8), visit 6 (Day 15) & visit 7 (Day 22). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OCS-01 1.5% mg/mL QD | 0/51 (0%) | 0/51 (0%) | 17/51 (33.3%) |
| OCS-01 1.5% mg/mL BID | 0/51 (0%) | 1/51 (2%) | 10/51 (19.6%) |
| Placebo (Vehicle) BID | 1/51 (2%) | 1/51 (2%) | 20/51 (39.2%) |
| Event | OCS-01 1.5% mg/mL QD | OCS-01 1.5% mg/mL BID | Placebo (Vehicle) BID |
|---|---|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/51 | 0/51 | 1/51 |
| noninfectious endophthamitisEye disorders | 0/51 | 1/51 | 0/51 |
| AnemiaBlood and lymphatic system disorders | 0/51 | 0/51 | 1/51 |
| Event | OCS-01 1.5% mg/mL QD | OCS-01 1.5% mg/mL BID | Placebo (Vehicle) BID |
|---|---|---|---|
| conjunctival hyperaemiaEye disorders | 3/51 | 2/51 | 8/51 |
| corneal edemaEye disorders | 5/51 | 1/51 | 8/51 |
| eye painEye disorders | 0/51 | 0/51 | 4/51 |
| anteror chamber inflammationEye disorders | 1/51 | 3/51 | 0/51 |
| iritisEye disorders | 3/51 | 0/51 | 2/51 |
| vitreous detachmentEye disorders | 2/51 | 1/51 | 0/51 |
| posterior capsule opacificationEye disorders | 2/51 | 0/51 | 0/51 |
| eye inflammationEye disorders | 1/51 | 0/51 | 2/51 |
| visual acuity reducedEye disorders | 0/51 | 0/51 | 2/51 |
| foreign body sensation in eyesEye disorders | 1/51 | 1/51 | 1/51 |
| Age, Categorical(Participants) | OCS-01 1.5% mg/mL QD | OCS-01 1.5% mg/mL BID | Placebo (Vehicle) BID | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 13 | 22 | 15 | 50 |
| >=65 years | 38 | 29 | 36 | 103 |
| Age, Continuous(years) | OCS-01 1.5% mg/mL QD | OCS-01 1.5% mg/mL BID | Placebo (Vehicle) BID | Total |
|---|---|---|---|---|
| Mean | 68.0 ± 6.86 | 65.8 ± 6.59 | 67.5 ± 8.41 | 67.1 ± 7.34 |
| Sex: Female, Male(Participants) | OCS-01 1.5% mg/mL QD | OCS-01 1.5% mg/mL BID | Placebo (Vehicle) BID | Total |
|---|---|---|---|---|
| Female | 33 | 36 | 32 | 101 |
| Male | 18 | 15 | 19 | 52 |
| Race (NIH/OMB)(Participants) | OCS-01 1.5% mg/mL QD | OCS-01 1.5% mg/mL BID | Placebo (Vehicle) BID | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 3 | 8 | 4 | 15 |
| White | 47 | 42 | 47 | 136 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | OCS-01 1.5% mg/mL QD | OCS-01 1.5% mg/mL BID | Placebo (Vehicle) BID | Total |
|---|---|---|---|---|
| United States | 51 | 51 | 51 | 153 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2019 to primary completion in Jan 2020, 4 months.
Results were first posted in Mar 2022, 2 years 1 month after primary completion. A results delay was requested in Jan 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oculis